Particularly, this progress has led to a significant improvement in the OS of melanoma patients with unresectable or metastatic disease, with the definition of two immunotherapy treatments, based on the double targeting of PD1 and CTLA-4 or PD1 and LAG-3, that now represent the standard of care for these patients. This evidence concerns the gene LAG3 and melanoma.